Article Text

Download PDFPDF
Update on drugs for overactive bladder syndrome
  • Relevant BNF section: 7.4.2


Around 1.5% of adults in Europe and the USA have urge urinary incontinence (involuntary leakage immediately preceded or accompanied by urgency).1,2 This is usually due to overactive bladder syndrome (defined as urgency, with or without urge incontinence, and usually with frequency and nocturia),1 which occurs in around 12% of adults, and is similarly prevalent in men and women.2 We last reviewed this condition in 2001.3 Since then, two new antimuscarinic drugs, ▼darifenacin (Emselex) and ▼solifenacin (Vesicare) have been licensed in the UK for urge incontinence and/or increased urinary frequency and urgency (as may occur in patients with overactive bladder syndrome),4,5 as have ▼transdermal oxybutynin (Kentera) and modified-release formulations of tolterodine (Detrusitol XL) and propiverine (Detrunorm XL).68 Here we review the place of these newer drugs and formulations.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 7.4.2

View Full Text